+1 (917) 893 7512

  • #
  • #
  • #
Global Glaucoma Treatment Market 2015 Edition - Business Market Research Reports

Global Glaucoma Treatment Market - Trends And Opportunities: 2015 Edition

Publish Date:August 2015
No. of Pages:80

Format : Adobe Reader (PDF) Instant delivery

US$ 1,200.00

Scope of the report

The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2015 Edition)” analyzes the potential opportunities, challenges, demand drivers and significant trends representing the Glaucoma treatment market. The report elucidates facts on the glaucoma treatment market as supplemented by the latest available statistics. It also profiles and analyzes the leading four companies operating in this industry with latest data and a brief overview of their business and financial performance along with a brief discussion of their future business strategies. The report gives valuable insight into technology used in glaucoma treatment market, its demand in various geographies. In the report, we also try to study the growth pattern in the prescriptions and revenue earned by the glaucoma treatment companies and the latest trends concerning glaucoma treatment market. Most importantly, we have analyzed the current market size and project future market size of the overall glaucoma treatment market for the years to come.

Company Coverage

Biolite Israeli
Pfizer Inc.
Merck & Co. Inc.
Alcon ( A division of Novartis)

Products Covered

Combination Market
Carbonic Anhydrase Inhibitor
Beta Blocker
Alpha Agonist & Cholinergic
Surgical Devices

Executive Summary

The global Glaucoma market has been growing rapidly since the past several years mainly due to innovation such as introduction of IOPtiMa, OTP-TX, anti-VEGF therapy, photodynamic therapy (PDT) laser photocoagulation, Rhopressa, latanoprost and Vesneo. Among the several varieties of drugs and surgeries available in the market, the demand for drugs such as Prostaglandins which includes Trabatan, Lumbigan are the highest due to its high efficiency in treating glaucoma. Vesneo has shown a superior intraocular pressure reduction effect on beta-blocker timolol, the most widely used comparator in registration trials for glaucoma, in two phase 3 studies.

Globally, the major factors contributing to the growth of Glaucoma treatment market is the higher number of glaucoma patients from the U.S, Europe and Japan. Novel therapies for glaucoma are constantly being investigated by research and development teams of various pharmaceutical companies, at different stages. It can be predicted that novel therapies that work in conjunction with current drugs, such as Prostaglandins, will likely be increasingly common in the near future.

Growth of the Glaucoma treatment market could also be attributed to North America where the number of patients suffering from glaucoma is the highest among the rest of the U.S and also from emerging markets such as France and Singapore driven by rapid increase of old age population. Moreover, the Asian market is expected to become a huge potential market for glaucoma surgery devices in the foreseeable future, as it is expected to grow at comparatively the fastest among all other regions. It is estimated that by 2020, 11 million individuals will have vision loss due to glaucoma.

Glaucoma market is seen as a diversifying risk to other lines of ophthalmic treatment business and is attracting more and more revenue. Glaucoma treatment companies are launching new technologies and adopting new strategies in the industry and making significant investments.

Tags :

1. Executive Summary

2. Glaucoma: A Cause for Vision Loss

2.1 Overview
2.2 Types of Glaucoma
2.3 Prevention and Treatment of Glaucoma

3. Global Glaucoma Treatment Market: Size and Growth

4. Glaucoma Market: Regional/Country Analysis

4.1 U.S Glaucoma Treatment Market Analysis: Size and Growth
4.2 U.S Glaucoma Treatment Market Analysis: By Drugs

4.2.1 U.S Prostaglandin Market: Size and Segmentation
4.2.2 U.S Combination Market: Size and Segmentation
4.2.3 U.S Carbonic Anhydrase Inhibitors Market: Size and Segmentation
4.2.4 U.S Beta Blocker Market: Size and Segmentation
4.2.5 U.S Alpha Agonist and Cholinergic Market: Size and Segmentation

4.3 U.S Vesneo (Glaucoma) Market: An Analysis
4.4 U.S Glaucoma Surgical Devices Market: An Analysis
4.5 Europe7 Vesneo (Glaucoma) Market: An Analysis
4.6 Japan Glaucoma Treatment Market: An Analysis
4.7 Japan Glaucoma Treatment Market Analysis: By Drugs

4.7.1 Tapros Market Size: An Analysis
4.7.2 Cosopt Market Size: An Analysis
4.8 Japan Vesneo (Glaucoma) Market: An Analysis

5. Global Glaucoma Market Share: An Analysis

5.1 U.S Glaucoma Treatment Market Share: An Analysis
5.2 Japan Glaucoma Treatment Market Share: An Analysis

6. Market Dynamics Global Glaucoma Market

6.1 Growth Drivers Global Glaucoma Market

6.1.1 Innovation
6.1.2 Rising Old Age Population
6.1.3 Rising Global Healthcare expenditure
6.1.4 Alternative Drug Delivery Methods to Treat Glaucoma

6.2 Challenges: Global Glaucoma Market

6.2.1 Vision Loss and Bleeding from Eye
6.2.2 Infection
6.2.3 Side Effects of Glaucoma Drugs

6.3 Market Trends: Global Glaucoma Market

6.3.1 Anti-VEGF Market Opportunity will continue to Expand
6.3.2 New Glaucoma Drugs to Accelerate Glaucoma Treatment Market
6.3.3 Glaucoma Treatment Ideal for Treating TB
6.3.4 Glaucoma being the second largest reason for blindness
6.3.5 New Treatments to Reduce Intra Ocular Pressure to Treat Glaucoma
6.3.6 Prostaglandin Drugs Most Popular For Glaucoma Treatment

7. Competitive Landscape: Global Glaucoma Market

World’s leading companies and their comparative analysis

8. Company Profiles: Global Glaucoma Market

8.1 Biolight Israeli

8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategies

8.2 Pfizer Inc.

8.2.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategies

8.3 Merck & Co. Inc.

8.3.1 Business Overview
8.3.2 Financial Overview
8.3.4 Business Strategies

8.4 Alcon (A division of Novartis)

8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategies
Figure 1: Diagrammatic Representation of a Normal Eye
Figure 2: Diagrammatic Representation of Developing Glaucoma
Figure 3: Diagrammatic Representation of Open Angle Glaucoma
Figure 4: Diagrammatic Representation of Angle Closure Glaucoma
Figure 5: Diagrammatic Representation of Argon Laser Trabeculoplasty
Figure 6: Diagrammatic Representation of Selective Laser Trabeculoplasty
Figure 7: Diagrammatic Representation of Laser Iridotomy
Figure 8: Diagrammatic Representation of Trabeculectomy
Figure 9: Diagrammatic Representation of Drainage System Surgery
Figure 10: Global Glaucoma Treatment Market-(US$ Million)-2012-2014
Figure 11: Total Number of Prescriptions issued Worldwide for Glaucoma Treatment-(Million)-2012-2014E
Figure 12: Global Glaucoma Treatment Market-(US$ Million)-2015-2019
Figure 13: Total Number of Prescriptions forecasted to be issued Worldwide for Glaucoma Treatment-(Million)-2015-2019
Figure 14: U.S Glaucoma Treatment Market-(US$ Billion)-2012-2014E
Figure 15: Total Number of Prescriptions issued in U.S for Glaucoma Treatment-(Million)-2012-2014E
Figure 16: U.S Glaucoma Treatment Market Forecast-(US$ Billion)-2015-2019
Figure 17: Total Number of Prescriptions issued in U.S for Glaucoma Treatment-(Million)-2015-2019
Figure 18: U.S Prostaglandin Market-(2012-2013)
Figure 19: U.S Trabatan Market-(2012-2013)
Figure 20: U.S Lumbigan Market-(2012-2013)
Figure 21: U.S Combination Market-(2012-2013)
Figure 22: U.S Cosopt Market-(2012-2013)
Figure 23: U.S Combigan Market-(2012-2013)
Figure 24: U.S Carbonic Anhydrase Inhibitors Market-(2012-2013)
Figure 25: U.S Carbonic Anhydrase Inhibitor Branded Market-(2012-2013)
Figure 26: U.S Beta Blocker Market-(2012-2013)
Figure 27: U.S Beta Blocker (Branded) Market-(2012-2013)
Figure 28: U.S Alpha Agonist and Cholinergic Market-(2012-2013)
Figure 29: U.S Alphagan Market-(2012-2013)
Figure 30: Expected Prevalence of Vesneo(Glaucoma) in U.S-(Millions)-2015-2020
Figure 31: Expected Prescriptions of Vesneo(Glaucoma) in U.S-(Millions)-2015-2020
Figure 32: U.S Glaucoma Surgical Devices Market-(US$ Billion)-2012-2014E
Figure 33: Expected Prevalence of Vesneo(Glaucoma) in Europe7-(Millions)-2015-2020
Figure 34: Expected Prescription of Vesneo(Glaucoma) in Europe7-(Millions)-2015-2020
Figure 35: Japan Glaucoma Treatment Market-(US$ Million)-20112-2014E
Figure 36: Japan Glaucoma Drug Treatment Market-(US$ Million)-2010-2013
Figure 37: Japan Tapros Market-(US$ Million)-2010-2013
Figure 38: Japan Cosopt Market-(US$ Million)-2010-2013
Figure 39: Expected Prevalence of Vesneo in Japan-(Million)-2015-2020
Figure 40: Expected Prescriptions of Vesneo in Japan-(Million)-2015-2020
Figure 41: Global Glaucoma Market Share-(By Region)-2013
Figure 42: Break-Up of U.S. Glaucoma Treatment Market-(By Treatment Types)-2013
Figure 43: Break-Up of Glaucoma Treatment Market-(By Drug Types)-2013
Figure 44: Break-Up of Prostaglandin Market for Glaucoma Treatment-(2013)
Figure 45: Break-Up of Combination Market for Glaucoma Treatment-(2013)
Figure 46: Break-Up of Carbonic Anhydrase Market for Glaucoma Treatment-(2013)
Figure 47: Break-Up of Beta Blocker Market for Glaucoma Treatment-(2013)
Figure 48: Break-Up of Alpha Agonist and Cholinergic Market for Glaucoma Treatment-(2013)
Figure 49: Japan Glaucoma Market Share-(By Treatment Types)-2013
Figure 50: Japan Glaucoma Market Share-(By Drug Types)-2013
Figure 51: Fluid Percolation through Fluid Intact Thinned Sclera by IOPtima
Figure 52: Rising Global Old Age Population-(Billion)-1990-2035E
Figure 53: Global Healthcare Expenditure-(US$ Trillion)-2009-2013
Figure 54: Break-Up of Eye Drop Types for Glaucoma Treatment-(By Popularity)
Figure 55: Market share of leading companies in Glaucoma Treatment-(Surgical Devices)-2013
Figure 56: Biolight Israeli Consolidated Revenue-(US$ Million)-2011-2014
Figure 57: Biolight Israeli Revenue Break-up-(Sector)-2014
Figure 58: Biolight Israeli Revenue Break-up-(Sector)-2013
Figure 59: Expenses in Research and Development- (US$ Million)-2011-2014
Figure 60: Pfizer Revenue from Xalatan and Xalacom-(US$ Million)-2012-2014
Figure 61: Pfizer Consolidated Net Income-(US$ Million)-2012-2014
Figure 62: Merck & Co. Revenue of Cosopt/Trusopt-(US$ Million)-2012-2014
Figure 63: Consolidated Net Income-(US$ Billion)-2012-2014
Figure 64: Alcon Consolidated Revenue-(US$ Million)-2011-2014
Figure 65: Alcon Revenue Break-Up by Franchises-(Percentage)-2013
Figure 66: Alcon Revenue Break-Up of Ophthalmic Pharmaceuticals-(Percentage)-2013
Figure 67: Alcon Revenue Break-Up by Franchises-(Percentage)-2014
Table 1: List of Tests for Glaucoma Detection
Table 2: List of Drugs Used in U.S Glaucoma Treatment Market-(2013)
Table 3: List of Alternative Drug Delivery Methods to Treat Glaucoma